PRELUDE THERAPEUTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 USD | -0.27% |
|
-0.40% | -13.58% |
Presenter SpeechUnknown Analyst (Analysts)Welcome, everyone, to the Prelude Therapeutics prese...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Calendar
11/11/2024
- Q3 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.69
USD
Average target price
4.75
USD
Spread / Average Target
+28.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.58% | 203M | |
| +21.85% | 46.44B | |
| +37.63% | 39.1B | |
| -8.05% | 38.76B | |
| +29.04% | 31.24B | |
| -13.75% | 25.8B | |
| +10.65% | 25.9B | |
| +38.43% | 13.12B | |
| -6.92% | 11.32B | |
| -12.29% | 10.68B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10
